GENFIT: Technical Corrections to the Results of the January 25, 2021 Bondholders Meeting with No Impact on Resolutions’ App...
27 Janvier 2021 - 9:30PM
GENFIT: Technical Corrections to the Results of the January 25,
2021 Bondholders Meeting with No Impact on Resolutions’ Approval
Lille, France; Cambridge, MA; January
27, 2021 - GENFIT (Nasdaq and Euronext:
GNFT), a late-stage biopharmaceutical company dedicated to
improving the lives of patients with metabolic and liver diseases
(the “Company”), today announced that technical
corrections were made to the voting results of the holders of the
convertible bonds issued by the Company on October 16, 2017 (the
“OCEANEs”) at the Bondholders Meeting which took
place on January 25, 2021 (the “Bondholders
Meeting”). These corrections have no impact on the
fact that all of the resolutions by the Bondholders Meeting were
approved, and are the result of corrections made by BNP Paribas
Securities Services, the external provider in charge of
centralizing the Bondholders Meeting votes. They are not the result
of any action or responsibility of the Company.
The Bondholders Meeting quorum remains unchanged
(70.88%) and the settlement operations for the partial buyback of
the 2,895,260 OCEANEs that certain bondholders have agreed to sell
to the Company will take place as planned by January 29, 2021.
BNP Paribas Securities Services corrected the
Bondholders Meeting votes after rechecking all bondholders’ voting
instructions. The results are as follows:
Resolution n°1:Votes for: 3,799,307Votes
against: 511,300Abstain : 0Resolution n°1 is adopted with 88.14 %
of votes (compared to 100% of votes as initially announced).
Resolution n°2Vote for: 3,799,307Vote against:
184,000Abstain : 327,300Resolution n°2 is adopted with 88.14% of
votes (compared to 100% of votes as initially announced).
Resolution n°3Vote for: 3,799,307 Vote against:
184,000Abstain : 327,300Resolution n°3 is adopted with 88.14% of
votes (compared to 100% of votes as initially announced).
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to improving the lives of patients with cholestatic and
metabolic chronic liver diseases. GENFIT is a pioneer in the field
of nuclear receptor-based drug discovery, with a rich history and
strong scientific heritage spanning more than two decades. GENFIT
is currently enrolling in ELATIVE™, a Phase 3 clinical trial
evaluating elafibranor in patients with Primary Biliary Cholangitis
(PBC). As part of GENFIT’s comprehensive approach to clinical
management of patients with liver disease, the Company is also
developing NIS4™, a new, non-invasive blood-based diagnostic
technology which could enable easier identification of patients
with at-risk NASH. NIS4™ technology has been licensed to
LabCorp in the U.S. and Canada for the development and
commercialization of a blood-based molecular diagnostic test
powered by NIS4™ technology. GENFIT has facilities in Lille and
Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded
company listed on the Nasdaq Global Select Market and on
compartment B of Euronext’s regulated market in Paris (Nasdaq and
Euronext: GNFT). www.genfit.com
FORWARD LOOKING STATEMENTS
This press release is not an advertisement and
does not constitute a prospectus for the purpose of the Prospectus
Regulation.
This press release contains certain
forward-looking statements with respect to GENFIT, including those
within the meaning of the Private Securities Litigation Reform Act
of 1995, with respect to GENFIT, including statements regarding the
partial buyback of a number of OCEANEs convertible bonds. The use
of certain words, including “consider”, “contemplate”, “think”,
“aim”, “expect”, “understand”, “should”, “aspire”, “estimate”,
“believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or
“have confidence” or (as the case may be) the negative forms of
such terms or any other variant of such terms or other terms
similar to them in meaning is intended to identify forward-looking
statements. Although the Company believes its projections are based
on reasonable expectations and assumptions of the Company’s
management, these forward-looking statements are subject to
numerous known and unknown risks and uncertainties, which could
cause actual results to differ materially from those expressed in,
or implied or projected by, the forward-looking statements. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including in
relation to safety, biomarkers, progression of, and results from,
its ongoing and planned clinical trials, review and approvals by
regulatory authorities of its drug and diagnostic candidates,
exchange rate fluctuations and the Company’s continued ability to
raise capital to fund its development, as well as those risks and
uncertainties discussed or identified in the Company’s public
filings with the AMF, including those listed in Chapter 2 “Main
Risks and Uncertainties” of the Company’s 2019 Universal
Registration Document filed with the AMF on 27 May 2020 under n°
D.20-0503 and in Section 2 “Risk Factors” of the Company’s
Amendment to the Universal Registration Document filed with the AMF
on 22 December 2020 under n° D.20-0503-A01, which are available on
the Company’s website (www.genfit.com) and on the website of the
AMF (www.amf-france.org) and public filings and reports filed with
the U.S. Securities and Exchange Commission (“SEC”) including the
Company’s 2019 Annual Report on Form 20-F filed with the SEC on May
27, 2020. In addition, even if the Company’s results, performance,
financial condition and liquidity, and the development of the
industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. These forward-looking
statements speak only as of the date of publication of this
document. Other than as required by applicable law, the Company
does not undertake any obligation to update or revise any
forward-looking information or statements, whether as a result of
new information, future events or otherwise.
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120
Loos - FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: Technical Corrections to the Results of the January 25,
2021 Bondholders Meeting with No Impact on Resolutions’
Approval